

LITERATUR

Ausgabe: Implantologie Journal 1+2/21
Thema: Nichtchirurgische parodontale Regeneration
Autor: Min-Young Kim

1. Buti J, Baccini M, Nieri M, La Marca M, Pini-Prato GP. Bayesian network meta-analysis of root coverage procedures: ranking efficacy and identification of best treatment. *J Clin Periodontol.* 2013 Apr;40(4):372-86. doi: 10.1111/jcpe.12028. Epub 2013 Jan 24.
2. Cochran DL, King GN, Schoolfield J, Velasquez-Plata D, Mellonig JT, Jones A.:The effect of enamel matrix proteins on periodontal regeneration as determined by histological analyses. *J Periodontol.* 2003 Jul;74(7):1043-55.
3. Cortellini P, Tonetti MS.: Clinical and radiographic outcomes of the modified minimally invasive surgical technique with and without regenerative materials: a randomized-controlled trial in intra-bony defects. *J Clin Periodontol.* 2011 Apr;38(4):365-73. doi: 10.1111/j.1600-051X.2011.01705.x. Epub 2011 Feb 8.
4. Cortellini P, Tonetti MS.:Improved wound stability with a modified minimally invasive surgical technique in the regenerative treatment of isolated interdental intrabony defects.*J Clin Periodontol.* 2009 Feb;36(2):157-63. doi: 10.1111/j.1600-051X.2008.01352.x.
5. Cortellini P, Tonetti MS.:A minimally invasive surgical technique with an enamel matrix derivative in the regenerative treatment of intra-bony defects: a novel approach to limit morbidity.*J Clin Periodontol.* 2007 Jan;34(1):87-93.]
6. Hoffmann T, Richter S, Meyle J, Gonzales JR, Heinz B, Arjomand M, Sculean A, Reich E, Jepsen K, Jepsen S, Boedeker RH.: A randomized clinical multicentre trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part III: patient factors and treatment outcome. *J Clin Periodontol.* 2006 Aug;33(8):575-83.
7. Hüsamettin G, Staufenbiel I, Geurtsen W, Adam K: Die Granulationsgewebeerhaltende Technik in der regenerativen Periimplantitistherapie – ein Behandlungskonzept mit Fallberichten. *DZZ* 2019; 74 (1), 16-27.

8. Jepsen S, Topoll H, Rengers H, Heinz B, Teich M, Hoffmann T, Al-Machot E, Meyle J, Jervøe-Storm PM. Clinical outcomes after treatment of intra-bony defects with an EMD/synthetic bone graft or EMD alone: a multicentre randomized-controlled clinical trial. *J Clin Periodontol*. 2008 May;35(5):420-8. doi: 10.1111/j.1600-051X.2008.01217.x. Epub 2008 Mar 12.
9. Jepsen S, Heinz B, Jepsen K, Arjomand M, Hoffmann T, Richter S, Reich E, Sculean A, Gonzales JR, Bödeker RH, Meyle J. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal Class II furcation involvement in mandibular molars. Part I: Study design and results for primary outcomes. *J Periodontol*. 2004 Aug;75(8):1150-60.
10. Jepsen S, Heinz B, Wachtel H: Gemeinsame Stellungnahme der DGP/DGZMK Regenerative Therapie mit einem Schmelzmatrixprotein (Emdogain). Stand 01/2002. DZZ 49 (94).
11. McGuire MK, Scheyer ET, Nunn M. Evaluation of human recession defects treated with coronally advanced flaps and either enamel matrix derivative or connective tissue: comparison of clinical parameters at 10 years. *J Periodontol*. 2012 Nov;83(11):1353-62. doi: 10.1902/jop.2012.110373
12. Meyle J, Hoffmann T, Topoll H, Heinz B, Al-Machot E, Jervøe-Storm PM, Meiss C, Eickholz P, Jepsen S.: A multi-centre randomized controlled clinical trial on the treatment of intra-bony defects with enamel matrix derivatives/synthetic bone graft or enamel matrix derivatives alone: results after 12 months. *J Clin Periodontol*. 2011 Jul;38(7):652-60.
13. Meyle J, Gonzales JR, Bödeker RH, Hoffmann T, Richter S, Heinz B, Arjomand M, Reich E, Sculean A, Jepsen K, Jepsen S. A randomized clinical trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part II: secondary outcomes. *J Periodontol*. 2004 Sep;75(9):1188-95.
14. Pecanov-Schröder A. Emdogain „flapless“ im Fokus von Parodontologen und Implantologen. *Dent Implantologie* 2019 23(5):316-9.
15. Pecanov-Schröder A. Expertenrunde: Schmelzmatrixproteine und minimal-invasive Therapie. Wissenschaftliche und klinische Bewährung von Emdogain und Emdogain FL in der regenerativen Parodontaltherapie. <https://www.quintessenz-news.de/expertenrunde-schmelzmatrixproteine-und-minimal-invasive-therapie/> 30.07.2019. Zuletzt aufgerufen: 12.05.2020
16. Pecanov-Schröder A: „Schmelzmatrixproteine brachten den Durchbruch für die regenerative Parodontaltherapie“. *DZW* 2015;19:10-11.
17. Sculean A, Kiss A, Miliauskaitė A, Schwarz F, Arweiler NB, Hannig M. Ten-year results following treatment of intra-bony defects with enamel matrix proteins and guided tissue regeneration. *J Clin Periodontol*. 2008 Sep;35(9):817-24. doi: 10.1111/j.1600-051X.2008.01295.x.

18. Sculean A, Donos N, Schwarz F, Becker J, Brex M, Arweiler NB.:Five-year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol. 2004 Jul;31(7):545-9.
19. Straumann: Informationen zur Vorgehensweise und zur Nachsorge finden sich auf <http://ifu.straumann.com/de/home.html> (Zuletzt aufgerufen: 14.05.2020)
20. Wada Y, Mizuno M, Nodasaka Y, Tamura M.The effect of enamel matrix derivative on spreading, proliferation, and differentiation of osteoblasts cultured on zirconia. Int J Oral Maxillofac Implants. 2012 Jul-Aug;27(4):849-58.